Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome
To evaluate the overall response rate of the combination of 5-azacitidine + Lenalidomide in high risk MDS patients (INT-2 and High risk defined by IPSS), and patients with low and int-1 who are considered to be at high risk due to unfavorable additional factors.

* To evaluate the safety of the combination of 5-azacitidine + Lenalidomide in high risk MDS patients.
* To evaluate the hematological improvement rate.
* To evaluate the cytogenetic response rate.
* To evaluate the Progression free survival (PFS).
* To assess Quality of life.
Myelodysplastic Syndrome
DRUG: 5-Azacytidine and Lenalidomide
ORR, 2 years
PFS, 2 years
To evaluate the overall response rate of the combination of 5-azacitidine + Lenalidomide in high risk MDS patients (INT-2 and High risk defined by IPSS), and patients with low and int-1 who are considered to be at high risk due to unfavorable additional factors.

* To evaluate the safety of the combination of 5-azacitidine + Lenalidomide in high risk MDS patients.
* To evaluate the hematological improvement rate.
* To evaluate the cytogenetic response rate.
* To evaluate the Progression free survival (PFS).
* To assess Quality of life.